Cargando…
Origin and Therapies of Osteosarcoma
SIMPLE SUMMARY: Osteosarcoma is the most common malignant bone tumor in children, with a 5-year survival rate ranging from 70% to 20% depending on the aggressiveness of the disease. The current treatments have not evolved over the past four decades due in part to the genetic complexity of the diseas...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322921/ https://www.ncbi.nlm.nih.gov/pubmed/35884563 http://dx.doi.org/10.3390/cancers14143503 |
_version_ | 1784756422951567360 |
---|---|
author | Moukengue, Brice Lallier, Morgane Marchandet, Louise Baud’huin, Marc Verrecchia, Franck Ory, Benjamin Lamoureux, Francois |
author_facet | Moukengue, Brice Lallier, Morgane Marchandet, Louise Baud’huin, Marc Verrecchia, Franck Ory, Benjamin Lamoureux, Francois |
author_sort | Moukengue, Brice |
collection | PubMed |
description | SIMPLE SUMMARY: Osteosarcoma is the most common malignant bone tumor in children, with a 5-year survival rate ranging from 70% to 20% depending on the aggressiveness of the disease. The current treatments have not evolved over the past four decades due in part to the genetic complexity of the disease and its heterogeneity. This review will summarize the current knowledge of OS origin, diagnosis and therapies. ABSTRACT: Osteosarcoma (OS) is the most frequent primary bone tumor, mainly affecting children and young adults. Despite therapeutic advances, the 5-year survival rate is 70% but drastically decreases to 20–30% for poor responders to therapies or for patients with metastasis. No real evolution of the survival rates has been observed for four decades, explained by poor knowledge of the origin, difficulties related to diagnosis and the lack of targeted therapies for this pediatric tumor. This review will describe a non-exhaustive overview of osteosarcoma disease from a clinical and biological point of view, describing the origin, diagnosis and therapies. |
format | Online Article Text |
id | pubmed-9322921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93229212022-07-27 Origin and Therapies of Osteosarcoma Moukengue, Brice Lallier, Morgane Marchandet, Louise Baud’huin, Marc Verrecchia, Franck Ory, Benjamin Lamoureux, Francois Cancers (Basel) Review SIMPLE SUMMARY: Osteosarcoma is the most common malignant bone tumor in children, with a 5-year survival rate ranging from 70% to 20% depending on the aggressiveness of the disease. The current treatments have not evolved over the past four decades due in part to the genetic complexity of the disease and its heterogeneity. This review will summarize the current knowledge of OS origin, diagnosis and therapies. ABSTRACT: Osteosarcoma (OS) is the most frequent primary bone tumor, mainly affecting children and young adults. Despite therapeutic advances, the 5-year survival rate is 70% but drastically decreases to 20–30% for poor responders to therapies or for patients with metastasis. No real evolution of the survival rates has been observed for four decades, explained by poor knowledge of the origin, difficulties related to diagnosis and the lack of targeted therapies for this pediatric tumor. This review will describe a non-exhaustive overview of osteosarcoma disease from a clinical and biological point of view, describing the origin, diagnosis and therapies. MDPI 2022-07-19 /pmc/articles/PMC9322921/ /pubmed/35884563 http://dx.doi.org/10.3390/cancers14143503 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Moukengue, Brice Lallier, Morgane Marchandet, Louise Baud’huin, Marc Verrecchia, Franck Ory, Benjamin Lamoureux, Francois Origin and Therapies of Osteosarcoma |
title | Origin and Therapies of Osteosarcoma |
title_full | Origin and Therapies of Osteosarcoma |
title_fullStr | Origin and Therapies of Osteosarcoma |
title_full_unstemmed | Origin and Therapies of Osteosarcoma |
title_short | Origin and Therapies of Osteosarcoma |
title_sort | origin and therapies of osteosarcoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9322921/ https://www.ncbi.nlm.nih.gov/pubmed/35884563 http://dx.doi.org/10.3390/cancers14143503 |
work_keys_str_mv | AT moukenguebrice originandtherapiesofosteosarcoma AT lalliermorgane originandtherapiesofosteosarcoma AT marchandetlouise originandtherapiesofosteosarcoma AT baudhuinmarc originandtherapiesofosteosarcoma AT verrecchiafranck originandtherapiesofosteosarcoma AT orybenjamin originandtherapiesofosteosarcoma AT lamoureuxfrancois originandtherapiesofosteosarcoma |